Skip to main content

Animations

MJFF Publications

3611 - 3620 of 6570 Results
Title
Year
  • Year
  • 2011
  • 2026
  • 2019
  • 2020
  • 2024
  • 2023
  • 2025
  • 2021
  • 2020
  • 2012
  • Summary Details
    OPEN
    Title: Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets
    Journal Name: Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.bbadis.2011.07.004
    Citation Count: 61
  • Summary Details
    OPEN
    Title: Associating Resting-State functional connectivity and improvements in reactive balance in Parkinson’s Disease
    Journal Name: Neuroscience Letters
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neulet.2026.138584
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase
    Journal Name: Journal of Medicinal Chemistry
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1021/acs.jmedchem.8b01294
    Citation Count: 26
  • Summary Details
    OPEN
    Title: Autonomic dysfunction is associated with neuropsychological impairment in Lewy body disease
    Journal Name: Journal of Neurology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1007/s00415-020-09783-7
    Citation Count: 29
  • Summary Details
    OPEN
    Title: Validating new symptom emergence as a patient-centric outcome measure for PD clinical trials
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2024.107118
    Citation Count: 0
  • α-synuclein seed amplification in Parkinson's disease – Authors' reply
    2023
    Summary Details
    OPEN
    Title: α-synuclein seed amplification in Parkinson's disease – Authors' reply
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(23)00371-x
    Citation Count: 7
  • Summary Details
    OPEN
    Title: Identification of small molecule dimethyoxyphenyl piperazine inhibitors of alpha-synuclein fibril growth
    Journal Name: Scientific Reports
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1038/s41598-025-17658-y
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Common and rare variants in HFE are not associated with Parkinson's disease in Europeans
    Journal Name: Neurobiology of Aging
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2021.05.019
    Citation Count: 3
  • Summary Details
    OPEN
    Title: Constructing treatment episodes from concomitant medication logs: a prospective observational study
    Journal Name: BMJ Open
    Publisher: BMJ
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1136/bmjopen-2019-034305
    Citation Count: 4
  • Summary Details
    OPEN
    Title: Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.nbd.2012.05.012
    Citation Count: 57
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.